HSPA5 and primary cutaneous T-cell non-Hodgkin lymphoma: Altogether, these data suggest that pharmacological interventions targeting the ER stress pathway, especially those that target HSPA5/6, not only induce anti-CTCL effects that include a strong stress and apoptotic signaling response but also inhibit their immunosuppressive Th2 phenotype.